Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 05, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 950,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,401.99 pence per share.
- Treasury Holdings: 237,832,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,754,515,324 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on January 05, 2007, pursuant to shareholder authority granted at the Annual General Meeting on May 17, 2006. The total number of shares held in Treasury increased to 237,832,678.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 950,000 share repurchase based on the disclosed price of 1,401.99 pence.
- Confirm the updated share count for voting rights calculations (5,754,515,324 shares in issue).
- Review the company's remaining authorization for share buybacks under the May 2006 shareholder mandate.
- Check subsequent filings for the impact of this treasury share holding on earnings per share calculations.